Produced by 
JUN 30, 2016 08:00 AM PDT
Surveying expression of immune checkpoint markers in the tissue microenvironment
SPONSORED BY: Advanced Cell Diagnostics
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE
3 19 2217

Speakers:
  • Research Scientist, R&D, Advanced Cell Diagnostics (ACD)
    Biography
      Dr. Jeffrey Kim is an research scientist at Advanced Cell Diagnostics (ACD) in Newark, California. Dr. Kim obtained his Ph.D. in molecular biology investigating how nutrient metabolism impacts gene expression to alter chronic disease states at the University of Connecticut. Afterwards, he completed a postdoctoral fellowship at the University of California-Davis looking at oncometabolite metabolism in renal cell carcinoma as well as the role of docosahexaenoic acid-derived metabolites on tumor angiogenesis. In addition, he previously completed a fellowship at the National Institutes of Health examining the influence of various fatty acids on brain development by combining the powerful tools of mass spectrometry and imaging.

    Abstract:

    DATE:  June 30, 2016
    TIME:  8:00am Pacific time, 11:00am Eastern time

    Focusing solely on malignant cancer cells and the genes that they express is modestly just a glimpse of the larger picture. The tumor microenvironment (TME) plays an important role in both tumor progression and the potential treatment response; identifying the key players involved in this environment could further reveal the immune system’s potential to regulate cancer. To achieve this, we used RNAscope® Assay to visualize immune checkpoint markers in the TME of non-small cell lung carcinoma biopsies from patients. Detection of co-expressed markers revealed a diverse pattern, highlighting intratumor heterogeneity within each tumor. Information derived from this study may reveal potential insight into combination therapies targeted against different checkpoint pathways.
     
    Learning objectives:

    • Understand how gene expression can be distinctly revealed with RNAscope in formalin-fixed, paraffin-embedded tissues with reliable consistency.
    • Learn how screening for checkpoint markers in the TME can help assess potential effective therapies.

    Show Resources
    Show Resources
    Connect with us